Glowing dyes reveal where IBD drugs hit or miss
NCT ID NCT07258641
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tests a new imaging method to see if two IBD drugs (adalimumab and risankizumab) actually reach the inflamed gut tissue. 30 adults with ulcerative colitis or Crohn's disease will receive a tiny dose of fluorescent-labeled drug before a routine colonoscopy. The goal is to predict who will respond to treatment and avoid ineffective therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9713GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.